Abstract: A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period time that is less than 60 minutes.

Abstract: A dry powder suitable for inhalation n a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period of time that is less than 60 minutes.

Abstract: The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. On of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.

Abstract: A powder formulation for inhalation comprising a macromolecule and a crystalline carrier material.

Abstract: A DPI device comprising a dispensing chamber for receiving a discrete dose of medicament-containing powder and means for delivering said dose from the dispensing chamber to a patient in an air-flow that passes from the chamber to the patient via a mouth-piece along a first air passage that comprises de-agglomerating means, the device additionally comprises a second air passage in fluid communication with the dispensing chamber and the mouth-piece and which by-passes the de-agglomerating means and which is located such that it receives a portion of said air-flow that is free, or substantially free, of powder.

Abstract: A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period time that is less than 60 minutes.

Abstract: A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period time that is less than 60 minutes.

Abstract: A pharmacological powder for inhalation comprising fine particles of a drug and particles of a force-controlling agent, wherein the particles of said force-controlling agent are disposed on the surface of the active particles as either a particulate coating, or as a continuous or discontinuous film. The powder may further comprise particles of a carrier material for supporting the drug particles. The force-controlling agent may be selected from: amino acids, peptides and polypeptides having a molecular weight of from 0.25 to 1000 KDa; phospholipids; titanium dioxide; aluminium dioxide; silicon dioxide; starch; and salts of fatty acids. Also disclosed is a method of making such a powder for inhalation comprising mixing a force-controlling agent with particles of one or more pharmacologically active materials to obtain a mixture in which the particles of said force-controlling agent are disposed on the surface of the active particles as either a particulate coating, or as a continuous or discontinuous film.

Abstract: A pharmaceutical aerosol formulation comprising formoterol fumarate di-hydrate in suspension, and a steroid in suspension, and a propellant, ethanol, and optionally a surfactant, wherein the formoterol fumarate di-hydrate has a water content of about 4.8 to 4.28% by weight.

Abstract: A pharmaceutical aerosol formulation comprising formoterol fumarate di-hydrate in suspension, and a steroid in solution, and a propellant, ethanol, and optionally a surfactant, wherein the formoterol fumarate di-hydrate has a water content of about 4.8 to 4.28% by weight, more particularly about 4.5 to 4.28%.

Abstract: A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate . The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period time that is less than 60 minutes.

Abstract: The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. One of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.

Abstract: The present invention relates to a process for the production of a natural mushroom extract by addition of an enzyme composition to a mushroom preparation.

Abstract: The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. One of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.

Abstract: In a phase matching circuit for generating a system clock signal for an incoming data signal from a locally existing clock signal, a delay signal is calculated from the detected phase position of the data signal in that a memory addressed with the detected phase position outputs an allocated delay signal. In a specific embodiment, the memory is supplied with an address that is compensated by the most recently identified delay. In a further development, a control comprising the memory shares circuits for a number of data signals. The phase matching, which automatically recognizes a jitter compatibility more suitable for the clocking than the jitter compatibility employed at the moment, can be completely integrated and avoids circuit areas that are operated with a higher bit repetition rate than that of the clock signal.

Abstract: A pressure-liquefied propellant mixture for aerosols, comprising dinitrogen monoxide and a hydrofluoroalkane having 1 to 3 carbon atoms, in particular 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane, makes possible an improvement in the wetting properties of pharmaceutically active compounds, whereby the formulation problems existing with hydrofluoroalkanes can be overcome with respect to suspension and solution aerosols and thus improved medicinal aerosol formulations can be obtained. With the aid of dinitrogen monoxide, it is also possible to influence the pressure and thus the particle size distribution specifically and, by displacement of oxygen from the hydrofluoroalkanes, to improve the storage stability of oxidation-sensitive active compounds. If desired, the propellant mixture can additionally contain carbon dioxide.

Abstract: The use of solid, pharmaceutically acceptable salts of cromoglycic acid and/or nedocromil as carriers in a therapeutically and prophylactically inefficacious amount in suspension aerosol formulations of pharmaceutical active compounds improves the dispersion properties, increases the chemical and physical stability of moisture-sensitive active compounds, makes possible a more accurate dosage, in particular even of low-dose active compounds, and as a rule permits the abandonment of surface-active agents.

Abstract: A method is provided for initiating a configuration after the interruption of at least two ring-shaped networks arranged in parallel. After the appearance of malfunctions in the ring lines and ring switching matrix devices in at least two-of-n ring-shaped networks, a configuring in the sense of forming those ring network portions that are still intact into a new ring-shaped network is initiated. Based on the knowledge of the position of the subscriber equipment (interpretation of the address table information) and on the transmission of interrupt information given ring interruptions, the configuring or, respectively, "loop back" connecting is initiated after the identification of the reception and transmission of interrupt information or the identification of the transmission of interrupt information dependent on the position of the appertaining subscriber equipment.

Abstract: A circuit for parallel-to-serial or serial-to-parallel conversion uses a multi-stage structure for conversion of long data words section-by-section. Each section of the data word corresponds to length/width of the respective registers or latches of the circuit which are successively controlled by an executive sequencer to process the data word in these smaller sections. The section-by-section conversion provides, for a high data rate, a reduction in clock loading and power dissipation.

Abstract: A packet sequence is formed in a subscriber station which monitors a token ring network including a number of subscriber stations, the packet sequence containing an address recognition bit at a binary "0" state, a broadcast sequence identifying the packet information as a broadcast packet sequence, and the information field thereof containing either an address signaling request or an address signaling request in the address of its own subscriber station. In the respective following subscriber stations, the received binary state of the address recognition bit is modified to a binary "1" and a further broadcast packet information sequence is formed such that the address recognition bit contains a binary "0" and the most-recently received address is entered into the information field with either the address of the preceding subscriber station or with its own address.